Related Experiment Video
Updated: Feb 24, 2026

Primary Culture of Mouse Dopaminergic Neurons
Published on: September 8, 2014
Microglia may compensate for dopaminergic neuron loss in experimental Parkinsonism through selective elimination of
Hitomi Aono1, Mohammed Emamussalehin Choudhury1, Hiromi Higaki1
1Department of Molecular and Cellular Physiology, Graduate School of Medicine, Ehime University, Toon, Ehime, Japan.
Abstract:
Parkinson's disease (PD) symptoms do not become apparent until most dopaminergic neurons in the substantia nigra pars compacta (SNc) degenerate, suggesting that compensatory mechanisms play a role. Here, we investigated the compensatory involvement of activated microglia in the SN pars reticulata (SNr) and the globus pallidus (GP) in a 6-hydroxydopamine-induced rat hemiparkinsonism model. Activated microglia accumulated more markedly in the SNr than in the SNc in the model. The cells had enlarged somata and expressed phagocytic markers CD68 and NG2 proteoglycan in a limited region of the SNr, where synapsin I- and postsynaptic density 95-immunoreactivities were reduced. The activated microglia engulfed pre- and post-synaptic elements, including NMDA receptors into their phagosomes. Cells in the SNr and GP engulfed red fluorescent DiI that was injected into the subthalamic nucleus (STN) as an anterograde tracer. Rat primary microglia increased their phagocytic activities in response to glutamate, with increased expression of mRNA encoding phagocytosis-related factors. The synthetic glucocorticoid dexamethasone overcame the stimulating effect of glutamate. Subcutaneous single administration of dexamethasone to the PD model rats suppressed microglial activation in the SNr, resulting in aggravated motor dysfunctions, while expression of mRNA encoding glutamatergic, but not GABAergic, synaptic elements increased. These findings suggest that microglia in the SNr and GP become activated and selectively eliminate glutamatergic synapses from the STN in response to increased glutamatergic activity. Thus, microglia may be involved in a negative feedback loop in the indirect pathway of the basal ganglia to compensate for the loss of dopaminergic neurons in PD brains.
Insights
Activated microglia in Parkinson's disease (PD) models engulf synapses, potentially compensating for neuron loss. Suppressing this microglial activity worsens motor deficits, revealing a novel therapeutic target.
Area of Science:
- Neuroscience
- Cell Biology
- Pathology
Background:
- Parkinson's disease (PD) symptoms manifest late, after significant dopaminergic neuron loss in the substantia nigra pars compacta (SNc).
- Compensatory mechanisms are crucial for maintaining function despite neurodegeneration.
Purpose of the Study:
- Investigate the role of activated microglia in the substantia nigra pars reticulata (SNr) and globus pallidus (GP) in a rat model of Parkinson's disease.
- Determine if microglia phagocytose synaptic elements and if this impacts motor function.
Main Methods:
- Utilized a 6-hydroxydopamine-induced hemiparkinsonism rat model.
- Examined microglial activation markers (CD68, NG2) and synaptic markers (synapsin I, PSD-95) via immunohistochemistry.
- Tracked synaptic element engulfment using fluorescent tracers (DiI) and electron microscopy.
- Assessed the effects of glutamate and dexamethasone on primary microglia and in vivo.
Main Results:
- Activated microglia accumulated in the SNr, exhibiting phagocytic markers and engulfing pre- and post-synaptic elements, including NMDA receptors.
- Microglia phagocytosed STN-derived synaptic elements, and their phagocytic activity increased with glutamate exposure.
- Dexamethasone suppressed microglial activation in PD model rats, leading to worsened motor function and increased glutamatergic synaptic element expression.
Conclusions:
- Microglia in the SNr and GP are activated in PD models and selectively eliminate glutamatergic synapses from the subthalamic nucleus (STN).
- This microglial phagocytosis represents a compensatory mechanism, potentially within the basal ganglia's indirect pathway.
- Targeting microglial activity, rather than suppressing it, may offer a novel therapeutic strategy for Parkinson's disease.
Related Concept Videos
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Neural Regulation

